Clinical Trials Browser

Phase 2 × Terminated × Breast × Clear all

NCT03765983 2026-05-27

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

Phase 2 Terminated

17 enrolled 14 charts

Breast Neoplasms

NCT05085002 2026-05-14

A Study of Lerociclib in Participants With Advanced Breast Cancer

Phase 2 Terminated

100 enrolled 14 charts

Advanced Breast Cancer

NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Phase 2 Terminated

Breast Neoplasms, Heart Failure, Cardiotoxicity

NCT06617455 2026-05-06

VEnT

Phase 2 Terminated

Carcinoma, Intraductal, Noninfiltrating

NCT01472445 2026-04-23

Vitamin D and Breast Cancer: Does Weight Make a Difference?

Phase 2 Terminated

41 enrolled 16 charts

Breast Neoplasms, Obesity

NCT02874430 2026-04-22

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

Phase 2 Terminated

29 enrolled 11 charts

Breast Neoplasms

NCT05744375 2026-04-02

TRANSCENDER

Phase 2 Terminated

2 enrolled 10 charts

Breast Neoplasms

NCT04796324 2026-03-12

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Phase 2 Terminated

13 enrolled 8 charts

Breast Neoplasms

NCT05554354 2026-03-03

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Phase 2 Terminated

Anatomic Stage IV Breast Cancer AJCC v8

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

NCT03130439 2026-02-20

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

Phase 2 Terminated

27 enrolled 17 charts

Breast Neoplasms

NCT04095689 2026-01-23

INTEGRAL

Phase 2 Terminated

8 enrolled 10 charts

Triple Negative Breast Neoplasms

NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Phase 2 Terminated

Breast Carcinoma In Situ, Breast Neoplasms

NCT03289039 2026-01-22

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2 Terminated

21 enrolled 15 charts

Breast Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Triple Negative Breast Neoplasms

NCT04578106 2026-01-06

ELPIS

Phase 2 Terminated

5 enrolled 7 charts

Breast Neoplasms

NCT04986852 2025-12-30

Olinvacimab With Pembrolizumab in Patients With mTNBC

Phase 2 Terminated

Triple Negative Breast Neoplasms

NCT03225547 2025-12-23

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04113863 2025-12-18

ATRA

Phase 2 Terminated

Breast Neoplasm Female

NCT05583110 2025-12-10

TrasTUCAN

Phase 2 Terminated

Breast Neoplasms

NCT04916002 2025-12-05

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Phase 2 Terminated

77 enrolled 18 charts

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05954143 2025-11-20

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Phase 2 Terminated

11 enrolled 13 charts

Breast Neoplasms

NCT04024436 2025-11-13

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Phase 2 Terminated

64 enrolled 21 charts

Breast Neoplasms

NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Phase 2 Terminated

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

NCT04504916 2025-11-10

MK-2140-002

Phase 2 Terminated

102 enrolled 36 charts

BreastGastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT05169437 2025-10-29

PAVO

Phase 2 Terminated

22 enrolled 17 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT03901469 2025-10-07

TNBC

Phase 2 Terminated

115 enrolled 31 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04136912 2025-10-06

3-D Super Resolution Ultrasound Microvascular Imaging

Phase 2 Terminated

27 enrolled 12 charts

BreastHead & Neck

Breast Neoplasms, Thyroid Neoplasms

NCT04659603 2025-10-01

CARMEN-BT01

Phase 2 Terminated

50 enrolled 20 charts

BreastGastrointestinal

Breast Cancer Metastatic

NCT04216472 2025-09-30

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03535506 2025-09-26

WI223281

Phase 2 Terminated

17 enrolled 9 charts

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04191382 2025-09-18

AMEERA-4

Phase 2 Terminated

105 enrolled 16 charts

Breast Neoplasms

NCT04249622 2025-09-16

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Phase 2 Terminated

20 enrolled 13 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT07166367 2025-09-10

Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

Phase 2 Terminated

HER2-positive Breast Cancer

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Phase 2 Terminated

17 enrolled 16 charts

Breast Neoplasms, Meningeal Neoplasms

NCT01703754 2025-08-28

Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.

Phase 2 Terminated

12 enrolled 24 charts

Breast Neoplasms

NCT03862131 2025-07-29

PROACT

Phase 2 Terminated

49 enrolled 12 charts

BreastLymphoidOther hematologic neoplasmPlasma cellSarcomaThoracic

Breast Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Sarcoma, Neoplasms, Plasma Cell, Cardiotoxicity

NCT04227327 2025-07-29

HERMIONE-7

Phase 2 Terminated

Advanced Breast Cancer

NCT05300958 2025-07-22

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Phase 2 Terminated

Triple Negative Breast Neoplasms

NCT03248492 2025-06-26

DESTINY-Breast01

Phase 2 Terminated

253 enrolled 21 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT04720729 2025-06-22

MONDRIAN

Phase 2 Terminated

HER2-negative Metastatic Breast Cancer

NCT04789096 2025-06-06

TUGETHER

Phase 2 Terminated

Breast Neoplasms

NCT04251169 2025-06-03

TATEN

Phase 2 Terminated

20 enrolled 19 charts

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00538343 2025-05-29

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Phase 2 Terminated

Brain Neoplasms, Breast Neoplasms

NCT00195091 2025-05-16

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

Phase 2 Terminated

16 enrolled 5 charts

Breast Neoplasms

NCT04965688 2025-04-10

SPOCK

Phase 2 Terminated

2 enrolled 4 charts

Breast Neoplasms